PliaFX Flo Subtalar Fusion Study

November 16, 2026 updated by: Alastair Younger, St. Paul's Hospital, Canada

A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada

During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.

This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • British Colombia
      • Vancouver, British Colombia, Canada, V6Z 1Y6
        • St. Paul's Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. The subject is at least 19 years of age.
  2. The subject is considered to be skeletally mature.
  3. The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
  4. The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
  5. The patient may undergo a subtalar fusion as part of a triple arthrodesis.
  6. The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
  7. The patient consented for either an arthroscopic or open procedure.
  8. The subject is able to comply with all post-operative evaluations and visits.
  9. The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery

Exclusion Criteria:

  1. The subject has:

    • Severe osteoporosis
    • Neuromuscular impairment
    • Prior infection in the affected joint
  2. The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.

  3. The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).

  4. The subject is renal compromised.

  5. The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).

  6. The subject is undergoing a revision of a prior subtalar fusion.

  7. The subject has had a prior ankle joint fusion.

  8. An ankle joint replacement or ankle joint fusion may be performed during the same sitting.

  9. The subject has a BMI of > 50 kg/m2.

  10. The subject is known to be pregnant, or plans to become pregnant during the study period

  11. The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).

  12. The subject is unable to provide informed consent.

  13. The subject is unable to communicate with the research team.

  14. The subject is unable to comply with follow-up.

  15. The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry

  16. The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PliaFX Flo Allograft

Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure.

Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure.

No Intervention: No Graft

Participant will receive no graft during their Subtalar Arthrodesis procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone Bridging Percentage
Time Frame: Enrollment to last Follow-up visit (52 weeks)

Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively.

Enrollment to last Follow-up visit (52 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Foot and Ankle Measure (FAAM) Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Current Health Assessment Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Demographics Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)
Ankle Osteoarthritis Scale
Time Frame: Enrollment to last follow up visit (52 weeks)

Minimum value of 1, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
SF-36 Health Survey
Time Frame: Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2031

Study Registration Dates

First Submitted

October 5, 2026

First Submitted That Met QC Criteria

October 13, 2026

First Posted (Actual)

October 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • H26-01617

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.